Citi analyst Andrew Baum lowered the firm’s price target on GSK to 1,550 GBp from 1,975 GBp and keeps a Neutral rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- AnaptysBio, GSK announces Phase 3 RUBY trial results for JEMPERLI
- GSK reports EMA accepts marketing authorization application for momelotinib
- GSK’s phase 3 trial of Jemperli meets primary endpoint
- GSK price target lowered to 1,535 GBp from 1,650 GBp at Morgan Stanley
- Jim Simons’ Hedge Fund Renaissance Technologies is Buying These Stocks Now